JPS58172317A - 平滑筋細胞増殖抑制および脳腱黄色腫症検知用２６−ヒドロキシコレステロ−ル製剤 - Google Patents

平滑筋細胞増殖抑制および脳腱黄色腫症検知用２６−ヒドロキシコレステロ−ル製剤

Info

Publication number
JPS58172317A
JPS58172317A JP57107488A JP10748882A JPS58172317A JP S58172317 A JPS58172317 A JP S58172317A JP 57107488 A JP57107488 A JP 57107488A JP 10748882 A JP10748882 A JP 10748882A JP S58172317 A JPS58172317 A JP S58172317A
Authority
JP
Japan
Prior art keywords
hydroxycholesterol
cholesterol
serum
present
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57107488A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0319206B2 (https=
Inventor
ノ−マン・ビ−・ジヤヴイツト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS58172317A publication Critical patent/JPS58172317A/ja
Publication of JPH0319206B2 publication Critical patent/JPH0319206B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP57107488A 1982-04-01 1982-06-22 平滑筋細胞増殖抑制および脳腱黄色腫症検知用２６−ヒドロキシコレステロ−ル製剤 Granted JPS58172317A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/364,338 US4427668A (en) 1982-04-01 1982-04-01 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
US364338 1994-12-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP1253697A Division JPH02117617A (ja) 1982-04-01 1989-09-28 アテローム性動脈硬化症の抑制または軽減用２６―ヒドロキシコレステロール製剤

Publications (2)

Publication Number Publication Date
JPS58172317A true JPS58172317A (ja) 1983-10-11
JPH0319206B2 JPH0319206B2 (https=) 1991-03-14

Family

ID=23434054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP57107488A Granted JPS58172317A (ja) 1982-04-01 1982-06-22 平滑筋細胞増殖抑制および脳腱黄色腫症検知用２６−ヒドロキシコレステロ−ル製剤
JP1253697A Granted JPH02117617A (ja) 1982-04-01 1989-09-28 アテローム性動脈硬化症の抑制または軽減用２６―ヒドロキシコレステロール製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP1253697A Granted JPH02117617A (ja) 1982-04-01 1989-09-28 アテローム性動脈硬化症の抑制または軽減用２６―ヒドロキシコレステロール製剤

Country Status (2)

Country Link
US (1) US4427668A (https=)
JP (2) JPS58172317A (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4939134A (en) * 1988-09-19 1990-07-03 New York University 26-aminocholesterol and derivatives and analogs thereof in the regulation of cholesterol accumulation in body tissue
WO1991015213A1 (en) * 1990-04-02 1991-10-17 The University Of Colorado Foundation, Inc. Side-chain hydroxylated cholesterol derivatives, agents for dissolution of cholesterol gallstones
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
US5274088A (en) * 1992-07-02 1993-12-28 New York University Method for the preparation of (25r)-26-aminocholesterol
US5587368A (en) * 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
US20040121992A1 (en) * 2002-09-10 2004-06-24 Javitt Norman B. Therapeutic methods of reducing cholesterol accumulation
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Also Published As

Publication number Publication date
JPH0319206B2 (https=) 1991-03-14
JPH02117617A (ja) 1990-05-02
JPH0457647B2 (https=) 1992-09-14
US4427668A (en) 1984-01-24

Similar Documents

Publication Publication Date Title
Wculek et al. Metabolism of tissue macrophages in homeostasis and pathology
Maeba et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging
Taquet et al. Relations of cardiovascular risk factors to aortic pulse wave velocity in asymptomatic middle-aged women
US6083932A (en) Pharmaceutical compositions derived from ginseng and methods of treatment using same
Harris et al. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans
Schmidt et al. A study of the Influence of mevalonic acid and its metabolites on the morphology of swiss 3T3 cells.
Packard et al. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism.
JPS58172317A (ja) 平滑筋細胞増殖抑制および脳腱黄色腫症検知用２６−ヒドロキシコレステロ−ル製剤
KR101730504B1 (ko) 당뇨병 치료에서 라노스테인 및 복령 추출물의 용도
CN106317142A (zh) 具有抗自身免疫性肝炎作用活性的化合物及其制备方法
US5432058A (en) Method for measuring human cholesterol absorption using metabolically stable isotopes
CN109078011A (zh) 鸢尾苷元及其衍生物在防治胰岛素抵抗疾病药物中的应用
Kraemer et al. Inhibition of cholesterol synthesis by ketoconazole
Howard et al. Coordination of very low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: effects of obesity and non-insulin-dependent diabetes mellitus
Hamwi et al. Lipoatrophic diabetes
Robinson Preparation of Lysolecithin
Stein et al. Use of 3H-cholesteryl linoleyl ether for the quantitation of plasma cholesteryl ester influx into the aortic wall in hypercholesterolemic rabbits.
Marzetta et al. Conversion of plasma VLDL and IDL precursors into various LDL subpopulations using density gradient ultracentrifugation.
US4812443A (en) Methods for enhancing differentiation and proliferation of hematopoietic progenitor cells
Qu et al. Atractylodin targets GLA to regulate D‐mannose metabolism to inhibit osteogenic differentiation of human valve interstitial cells and ameliorate aortic valve calcification
Carlson et al. A case of massive hypertriglyceridemia corrected by nicotinic acid or nicotinamide therapy
Toda et al. Ultrastructural changes in the comb and aorta of chicks fed excess testosterone
TWI654980B (zh) 自牛樟芝提取之活性物質樟芝酸k及其用於抗糖尿病、抗高血脂、及降低肝臟脂質的用途
Ueda et al. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.
Packard et al. Effects of 1, 2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism.